← All trials
NCT05479058
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Nov 30, 2026
- First posted
- Jul 29, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Galapagos NVLead sponsor
- Galapagos NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.